Stockscreener 앱 받기
67.00
1.64%
1.08
시간 외 거래:
67.00
전일 마감가:
$65.92
열려 있는:
$65.56
하루 거래량:
1.39M
Relative Volume:
0.77
시가총액:
$14.90B
수익:
$4.04B
순이익/손실:
$557.10M
주가수익비율:
27.80
EPS:
2.4102
순현금흐름:
$916.70M
1주 성능:
-1.96%
1개월 성능:
+5.02%
6개월 성능:
+15.80%
1년 성능:
-17.95%
1일 변동 폭
$65.12
$67.07
1주일 범위
$65.00
$68.98
52주 변동 폭
$51.90
$84.39
홀로직 Stock (HOLX) Company Profile
명칭
Hologic Inc
전화
(508) 263-2900
주소
250 CAMPUS DRIVE, MARLBOROUGH, MA
HOLX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HOLX
Hologic Inc
|
67.00 | 14.66B | 4.04B | 557.10M | 916.70M | 2.4102 |
|
ISRG
Intuitive Surgical Inc
|
435.61 | 156.44B | 9.15B | 2.63B | 1.99B | 7.1661 |
|
BDX
Becton Dickinson Co
|
186.77 | 53.99B | 21.39B | 1.61B | 2.55B | 5.5609 |
|
RMD
Resmed Inc
|
269.70 | 39.41B | 5.15B | 1.40B | 1.65B | 9.5082 |
|
ALC
Alcon Inc
|
73.99 | 36.63B | 10.03B | 1.07B | 1.39B | 2.1549 |
|
WST
West Pharmaceutical Services Inc
|
262.95 | 18.78B | 2.96B | 487.70M | 344.00M | 6.6758 |
홀로직 Stock (HOLX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-07 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2025-08-18 | 업그레이드 | Argus | Hold → Buy |
| 2025-08-06 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-07-09 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-05-27 | 재확인 | Needham | Hold |
| 2025-03-03 | 다운그레이드 | Argus | Buy → Hold |
| 2025-02-06 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-02-03 | 다운그레이드 | Needham | Buy → Hold |
| 2024-12-13 | 개시 | Wolfe Research | Peer Perform |
| 2024-12-10 | 개시 | Jefferies | Hold |
| 2024-12-10 | 재확인 | Needham | Buy |
| 2024-10-01 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-06-27 | 개시 | Stephens | Overweight |
| 2024-04-03 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-07-14 | 업그레이드 | Needham | Hold → Buy |
| 2022-12-07 | 개시 | RBC Capital Mkts | Sector Perform |
| 2022-10-13 | 개시 | Mizuho | Buy |
| 2022-07-20 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-07-20 | 개시 | UBS | Neutral |
| 2022-07-18 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2022-04-25 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2022-04-04 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2021-12-15 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-10-15 | 재개 | Cowen | Outperform |
| 2021-10-14 | 개시 | Redburn | Neutral |
| 2021-07-06 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2020-11-20 | 다운그레이드 | Needham | Buy → Hold |
| 2020-11-05 | 재확인 | Needham | Buy |
| 2020-06-30 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2020-06-03 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2020-04-30 | 재확인 | Needham | Buy |
| 2020-04-30 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2020-04-07 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2020-03-27 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2020-01-13 | 재확인 | Needham | Buy |
| 2020-01-08 | 개시 | Wells Fargo | Equal Weight |
| 2020-01-07 | 개시 | Citigroup | Buy |
| 2020-01-02 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-09-26 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2019-08-01 | 재확인 | Needham | Buy |
| 2019-05-02 | 재확인 | Needham | Buy |
| 2019-01-31 | 재확인 | Needham | Buy |
| 2019-01-02 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2018-10-09 | 개시 | UBS | Neutral |
| 2018-09-13 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
모두보기
홀로직 주식(HOLX)의 최신 뉴스
Using fundamentals and technicals on Hologic Inc.Weekly Stock Recap & Daily Oversold Bounce Ideas - newser.com
Best data tools to analyze Hologic Inc. stock2025 Short Interest & Growth Focused Entry Point Reports - newser.com
Will Hologic Inc. rebound enough to break even2025 Earnings Impact & Low Volatility Stock Recommendations - newser.com
Short interest data insights for Hologic Inc.Risk Management & Free High Accuracy Swing Entry Alerts - newser.com
Risk adjusted return profile for Hologic Inc. analyzedAnalyst Upgrade & Reliable Intraday Trade Alerts - newser.com
HOLX's Enhanced Fibroid Treatment Portfolio Powers GYN Surgical Growth - The Globe and Mail
Is Most-Watched Stock Hologic, Inc. (HOLX) Worth Betting on Now? - Yahoo Finance
Mizuho Adjusts Price Target on Hologic to $70 From $75, Maintains Outperform Rating - MarketScreener
Real time breakdown of Hologic Inc. stock performanceIndex Update & Consistent Growth Equity Picks - newser.com
Statistical indicators supporting Hologic Inc.’s strengthWall Street Watch & Free Community Supported Trade Ideas - newser.com
Hologic, Inc. (HOLX) Stock Analysis: Exploring Growth Potential Amidst A 7.84% Upside - DirectorsTalk Interviews
Body Fat Measurement Market Poised for Growth, Expected to Hit - openPR.com
What Hologic (HOLX)'s FDA and CE Clearances for GI Assays Mean for Shareholders - Sahm
Hologic Inc. Stock Underperforms Friday When Compared To Competitors - 富途牛牛
Hologic (HOLX) Stock Moves -1.25%: What You Should Know - sharewise.com
Hologic (HOLX): Valuation in Focus After Key Regulatory Wins Expand Molecular Diagnostics Portfolio - Sahm
Pattern recognition hints at Hologic Inc. upside2025 Price Action Summary & Long-Term Growth Plans - newser.com
Is Hologic Inc. stock a buy before product launchesJobs Report & Verified Swing Trading Watchlist - newser.com
What the charts say about Hologic Inc. todayJuly 2025 Short Interest & Weekly Top Gainers Alerts - newser.com
Infectious Disease Testing Product Market 2025 | Industry - openPR.com
Can Hologic Inc. recover in the next quarterPortfolio Performance Summary & Low Risk Entry Point Guides - newser.com
Is Hologic Inc. stock trading near support levelsRate Cut & Weekly Breakout Watchlists - newser.com
Tools to assess Hologic Inc.’s risk profileFed Meeting & Weekly High Return Stock Forecasts - newser.com
Live market analysis of Hologic Inc.Trade Volume Report & Weekly Return Optimization Alerts - newser.com
Is Hologic Set for Growth After FDA Clears New Diagnostic Platform? - Yahoo Finance
Hologic, Inc. Hits Day High with 7.69% Surge in Stock Price - Markets Mojo
What Hologic (HOLX)'s FDA Clearance for GI Assays Means for Shareholders - Yahoo Finance
Hologic Expands Panther Fusion's Menu With Diagnostic Innovation - Yahoo Finance
3 Reasons HOLX is Risky and 1 Stock to Buy Instead - The Globe and Mail
Evercore ISI Group Upgrades Hologic (HOLX) - Nasdaq
Hologic (HOLX) Upgraded to Outperform by Evercore ISI Group | HO - GuruFocus
Hologic (HOLX) Shares Climb After Upgrade by Evercore ISI - GuruFocus
Evercore ISI Upgrades Hologic to Outperform From In Line, Adjusts Price Target to $78 From $69 - MarketScreener
Good practices post-Minerva Surgical, Inc. v. Hologic, Inc. | Latin America | Global law firm - Norton Rose Fulbright
Patrick Sullivan Elected to PerkinElmer Board - Photonics Spectra
What to do if you’re stuck in Hologic Inc.Earnings Overview Summary & AI Powered Market Entry Ideas - newser.com
How to Play HOLX Stock This Breast Cancer Awareness Month? - The Globe and Mail
How Hologic Inc. (HO1) stock reacts to monetary easingEarnings Growth Summary & Growth-Oriented Investment Plans - newser.com
Technical analysis overview for Hologic Inc. stock2025 Historical Comparison & Weekly Watchlist for Hot Stocks - newser.com
Will Dual FDA and CE Approvals for Panther Fusion Shape Hologic's (HOLX) Long-Term Story? - simplywall.st
What dividend safety rating applies to Hologic Inc. (HO1) stockWeekly Trend Summary & Weekly Top Gainers Alerts - newser.com
Should I buy Hologic Inc. (HO1) stock before earnings seasonPortfolio Return Summary & Risk Adjusted Buy and Sell Alerts - newser.com
Greenleaf Trust Purchases 173 Shares of Hologic, Inc. $HOLX - Defense World
Chart based analysis of Hologic Inc. trendsTake Profit & Fast Momentum Entry Tips - newser.com
Key metrics from Hologic Inc.’s quarterly dataJuly 2025 Levels & Proven Capital Preservation Tips - newser.com
HOLX Stock Gains on FDA & CE Approval for Automated Molecular GI Tests - MSN
홀로직 (HOLX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.44%
0.10%
자본화:
|
볼륨(24시간):